The abscopal effect is mediated by a systemic anti-tumor immune response and reflects the regression of non-irradiated metastatic lesions at a distance from the primary site of irradiation. This review will focus on understanding the biological rationale behind the abscopal effect of radiotherapy (RT), which has a recently renewed interest as a result of the successes achieved with immunotherapy and RT in combination. Both RT and immunotherapy are standard components of modern treatment regimens. Combination of these two modalities results in an increased response in the irradiated lesions themselves and the metastatic regions distant from the site of irradiation. We will summarize the abscopal effect of radiotherapy, in particular, the synergistic effect of RT and immunotherapy.
The analysis was based on a total of 468 patients with a median age of 66 years; 64% were younger than age 70, 19% were aged 70 to 75, and 17% were older than age 75. Among all patients, 82% were male. Approximately 94% had transitional cell carcinoma; 61% had clinical stage T2 tumors, and 35% had clinical stage T3. Median follow-up was 4.3 years for all patients and 7.8 years among 205 survivors.. Seventy-two percent of patients had a complete response to combined-modality therapy. The 5- and 10-year estimated overall survival rates were 57% and 36%, respectively; 5- and 10-year estimated disease-specific survival rates were 71% and 65%.. The majority of local failures in the bladder were non-muscle invasive, with an estimated 5- and 10-year incidence of 31% and 36%. The 5- and 10-year estimates for muscle-invasive failure rates were 13% and 14%, and 5- and 10-year estimates of distant metastases were 31% and 35%.. "This recurrence pattern underscores the need for careful post-treatment ...
In this study, we show in breast and colon carcinoma models that fractionated local radiotherapy to one palpable tumor can synergize with CTLA-4 blockade to induce antitumor T-cell immunity and inhibit a second palpable tumor outside the radiation field. This abscopal effect was not seen with radiotherapy alone. Although localized tumor irradiation by itself has been shown to enhance the generation of tumor-specific T cells in both preclinical models and patients, the therapeutic effects of this response remain undetermined (3, 19). Clearly, irradiation to the primary tumor was required in our models to induce growth inhibition of the secondary tumors outside the field because CTLA-4 blockade by itself was ineffective (Figs. 2 and 6). This is consistent with the hypothesis that radiation-induced immunogenic tumor cell death as well as its induction of danger signals contribute to generate an in situ vaccine (20-22). Whereas the response generated is not sufficient to be therapeutically ...
The addition of chemo-radiotherapy following surgery to remove pancreatic cancer tumours has been shown to reduce the risk of the cancer returning researchers in the USA have found.. The use of adjuvant radiotherapy has been a controversial topic over the years with many studies reporting conflicting evidence about whether or not the use of chemo- radiotherapy is beneficial.. The researchers from the Mayo Clinic in the USA, reporting in the International Journal of Radiation Oncology, Biology and Physics ((ASTRO)) studied 458 patients who had received pancreatic cancer surgery between March 1987 and January 2011. Out of those, 378 had received chemotherapy + chemo-radiotherapy after surgery and 80 had received only chemotherapy.. The chemotherapy in this study typically consisted of six cycles of gemcitabine and the chemo-radiotherapy consisted of 50.4Gy in 28 fractions concurrent with 5-fluorouracil. Of those who had received chemotherapy + chemo-radiotherapy following their surgery, 80 per ...
Results of radiation given to patients with AIDS-related high-grade CNS lymphoma have been disappointing, with short survival times due to infection complications. However, complete response has been documented after radiation in some patients. High-dose MTX will be used to improve the possibility of a greater antineoplastic response than that obtained by radiation alone. Since the underlying immunodeficiency state is not affected by therapy directed against the lymphoma, patients are still prone to life-threatening opportunistic infections or relapse of lymphomatous disease within the CNS. Accordingly, AZT will also be used in an attempt to alter the overall natural history of the disease.. Radiation begins on day 1 of therapy. Patients receive dexamethasone orally (PO) or by intravenous injection (IV) on days 1-10. MTX IV over 6 hours weekly for a total of 4 doses starts 1 week after completion of the cranial radiation. Leucovorin (LCV) IV or PO begins 6 hours after MTX has been completed over ...
Results of radiation given to patients with AIDS-related high-grade CNS lymphoma have been disappointing, with short survival times due to infection complications. However, complete response has been documented after radiation in some patients. High-dose MTX will be used to improve the possibility of a greater antineoplastic response than that obtained by radiation alone. Since the underlying immunodeficiency state is not affected by therapy directed against the lymphoma, patients are still prone to life-threatening opportunistic infections or relapse of lymphomatous disease within the CNS. Accordingly, AZT will also be used in an attempt to alter the overall natural history of the disease.. Radiation begins on day 1 of therapy. Patients receive dexamethasone orally (PO) or by intravenous injection (IV) on days 1-10. MTX IV over 6 hours weekly for a total of 4 doses starts 1 week after completion of the cranial radiation. Leucovorin (LCV) IV or PO begins 6 hours after MTX has been completed over ...
Generating and grading the abscopal effect: proposal for comprehensive evaluation of combination immunoradiotherapy in mouse models
Generating and grading the abscopal effect: proposal for comprehensive evaluation of combination immunoradiotherapy in mouse models
The standard of care for women with stage III/IVA endometrial cancer following surgery has been chemotherapy and radiation to prevent recurrence. But in a surprising new finding, radiation combined with chemotherapy did not ...
Combined-modality approaches for the treatment of non-small-cell lung cancer (NSCLC), head and neck cancer, and esophageal cancer offer survival benefits by improving locoregional control and treating micrometastatic disease. The taxanes are active, tolerable drugs in these solid tumors and have radiation-sensitizing activity. 1
Health,...Study confirms effectiveness of widely used approach experts say ...MONDAY Dec. 15 (HealthDay News) -- Men with locally advanced prostate...The addition of radiotherapy kept patients healthy much longer the Sw... The study will change practice in the treatment of locally advanced o...,Radiation,Plus,Hormone,Therapy,Cuts,Prostate,Cancer,Deaths,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
ABSTRACT: The multimodal therapy of ADHD with comorbidities proved its efficacy în comparison with the unimodal therapies. We will present the preliminary results of the first nine months of multimodal therapy, which has been applied on a number of 18 children and adolescents with ages between 8 and 17 years. ...
Chemotherapy, when combined with radiotherapy and/or surgery in the treatment of patients with head and neck cancer, appears to be most efficacious if it is given concurrently with radiotherapy. Concurrent chemotherapy and 1
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D: Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys 97(4): 687-699, March 2017 ...
More than 400 respected luminaries explore todays most effective strategies for managing every type of cancer by stage of presentation - discussing the role of all appropriate therapeutic modalities as well as combined-modality treatments. This multidisciplinary approach will help your cancer team collaboratively face the toughest clinical challenges and provide the best possible care for every cancer patient.
As a first step toward developing quantitative models, investigators recently developed a mathematical framework to simulate the systemic dissemination of T cells activated in response to focal therapy.
Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy. However, the efficacy of RT is limited by acquired tumor resistance leading to the risks of relapse and metastasis. To further enhance the efficacy of RT, with the renaissances of targeted immunotherapy (TIT), increasing interests are raised on RT combined with TIT including cancer vaccines, T-cell therapy, and antibody-based immune checkpoint blockers (ICB) such as anti-CTLA-4 and anti-PD1/PD-L1. In achieving a significant synergy between RT and TIT, the dynamics of radiation-induced response in tumor cells and stromal cells, especially the cross-talk between tumor cells and immune cells in the irradiated tumor microenvironment (ITME) as highlighted in recent literature are to be elucidated. The abscopal effect refereeing the RT-induced priming function outside of ITME could be ...
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreat
Improved dose tracking and a more multimodal approach are just a few of the ways treatment planning systems are delivering higher-quality radiation therapy
Loco-regional recurrences after intial surgery in patients with esophageal cancer remain a serious challenge to clinical oncologists. The NCCN Guidelines pointed out that a highly selected group of patients with local-regional tumor recurrence after initial surgery may be considered fit and able to tolerate concurrent radio-chemotherapy with a potential for cure [18]. In a line with the previous studies, our data indicated that salvage concurrent radio-chemotherapy was an active and promising treatment strategy for such patients, reaching a median OS of 13.3 months with tolerable side-effects.. The present protocol of concurrent radio-chemotherapy was completed in 74% (37/50) of the patients, and no serious treatment related toxicities were observed. The tumor response rate was nearly 72% in R-TP and R-FP group respectively, with a 3-year survival rate of 14%. These results are very similar to those reported in previous studies [13, 15]. Yamashita et al.[13] reported the results of radiotherapy ...
TY - JOUR. T1 - Adjuvant therapy in colorectal cancer. A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with methanol extraction residue of BCG, MER. AU - Robinson, E.. AU - Bartal, A.. AU - Cohen, Y.. AU - Milstein, D.. AU - Mekori, T.. PY - 1979/12/1. Y1 - 1979/12/1. N2 - Fifty-three patients with colorectal cancer (Dukes B 2 and C) were randomized after surgery. One group was treated by radio-and/or chemotherapy and the second by radio-and/or chemotherapy and MER. After 24 and 36 months a significant longer disease free interval, lower recurrence rate and better survival was found in the group treated by radio-chemo-and immunotherapy. Treatment was well tolerated and there were few local side effects from the MER injections. The long time efficacy of this adjuvant treatment whether it increases the cure rate or only delays recurrence requires longer follow-up.. AB - Fifty-three patients with colorectal cancer (Dukes B 2 and C) were randomized after surgery. ...
For all 250 patients, the overall median survival was 27 months, the cause-specific survival was 27 months, the local progression-free survival was 32 months, and distant metastasis-free survival was not achieved; and the respective 5-year survival rates were 27%, 32%, 45%, and 68%. CF achieved significantly inferior survival than either HFX RT alone or HFX RT-Pac/C (P = .0332 and P = .0013, respectively), and no difference was observed between the 2 HFX RT regimens (P = .1934). Only acute hematologic high-grade toxicity (grade ≥3) was more frequent with HFX RT-Pac/C than with either RT alone, whereas other toxicities were similar between the 3 treatment groups. ...
Rare Cancer News & Clinical Trials » Trial - Sarcoma » A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue ...
article{4430146, abstract = {Purpose: Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET) scan could be used to adapt treatment. Therefore, we started the randomized EORTC/LYSA/FIL Intergroup H10 trial evaluating whether involved-node radiotherapy (IN-RT) could be omitted without compromising progression-free survival in patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment. Patients and Methods: Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible. Here we report the clinical outcome of the preplanned interim futility analysis scheduled to occur after documentation of 34 events in the early PET-negative group. Because testing for futility in this noninferiority trial corresponds to testing the hypothesis of no difference, a ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Results Out of the 12 patients in the study, 6 did not receive radiotherapy either because they elected for subsequent radical surgery (3 patients) or were unfit for further treatment and underwent close follow-up (3 patients).. In the radiotherapy group, 2 patients had pre-op Long-Course Chemo-radiotherapy (LCCRT) with a good partial response, 2 were included in the national TEM and Radiotherapy in Early Rectal cancer (TREC) trial and had pre-op Short Course radiotherapy (SCRT) and 2 had adjuvant LCCRT + Papillon contact radiotherapy following TEM.. Median follow-up was 20 months. Patients not undergoing radial surgery had 3 monthly MR and sigmoidoscopy for 1 year and 6 monthly MR and sigmoidoscopy for a further 2 years.. In the no-radiotherapy group, 1 of the 3 patients who underwent subsequent radical surgery had involved mesorectal lymph nodes and 1 of those undergoing close follow-up without radical surgery developed mesorectal nodal recurrence. In radiotherapy group 1 patient, in the TREC ...
Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.
Selected high-risk patients with head and neck squamous cell carcinoma receive postoperative radiation therapy (RT), with or without concurrent chemotherapy, following primary surgical resection with the aim of improving locoregional control and surv
PubMed journal article [Combined-modality therapy for 150 cases of early-stage Hodgkins lymphoma were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
Positron emission tomography using fluoro-deoxy-glucose has demonstrated added value in the clinical management of patients with colorectal cancer [6]. This includes primary staging, detection of recurrence, prediction of individual prognosis, therapy response, and evaluation of treatment response as assessed in this investigation [8].. The interest in FDG-PET to assess tumour response to CRT began in the early 1990 s. Rectal cancer is a disease model of particular interest, not only for its high incidence, but also because an accurate and non-invasive method to evaluate response to preoperative CRT could lead to patients selection for minimally invasive surgical approaches or even selection of candidates for additional chemotherapy and observation without any kind of surgery [2, 3].. Experts at the Memorial Sloan-Kettering Cancer Center reported a pioneer prospective assessment of LARC response to preoperative CRT using FDG-PET in 2000 [9]. Today, literature is mixed in regard to the ability ...
The survival of children with non-Hodgkins lymphoma (NHL) has improved in the recent past through the systematic application of intensive therapy employing involved field radiation plus combinations...
Prognosis of patients who present with metastasized rectal cancer is poor. Without treatment, median survival is estimated at six months. Treatment options are available for the primary tumor and the metastatic disease. The primary tumor may be resected or treated with radiation therapy. Resection of the primary tumor is controversial, as it may not improve the quality of life in patients with a poor prognosis due to the metastatic disease. As the majority of patients with primary stage IV rectal cancer present with a locally advanced primary tumor, resection of the primary tumor would necessitate preoperative radiation therapy. Metastatic disease may respond to chemotherapy. In recent years, advances in chemotherapy have increased the response rate to 40 percent. Some patients presenting with liver or lung metastases are candidates for resection of their metastatic disease. Neoadjuvant chemotherapy may increase the fraction of patients with resectable metastatic disease, or may allow for ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-ener
In lieu of an abstract, here is a brief excerpt of the content: 136 CHAPTER 4 Radiation Therapy and Surgery Radiation therapy, like chemotherapy, is intended to selectively kill malignant cells while sparing normal cells as much as possible. Like chemotherapy, radiation therapy (also called radiotherapy) is most active against rapidly dividing populations of cells. Unlike most forms of chemotherapy, radiation can be applied locally, to specific areas of the body, rather than spreading throughout the entire body via the bloodstream. Radiation therapy may be used alone to treat people with localized lymphocytepredominant Hodgkin lymphoma or localized indolent NHL, but it is more commonly used in combination with chemotherapy (a form of combined modality treatment). Combined modality therapy is most frequently used to treat localized disease, generalized disease in which there is a specific bulky component, or an area of localized disease that remains after chemotherapy treatment. Combined modality ...
What changes are seen among patients with acromegaly after long-term multimodality therapy? Are these patients able to be biochemically controlled?
Cancer is a systemic (throughout the body) disease, no matter what your doctor tells you. Telling patients based on post-operation scans that we got it all is not the truth. Most cancers have been growing and spreading for 5 to 10 years before they are detected and diagnosed. Billions of cancer cells must be present to show up on any scan. Surgery can spread cancer. The word cure in oncology circles has up to fifty different definitions. The only real cure is the one where you live long enough to die from something other than cancer. These survivors are strong, and most utilize a protocol to treat cancer everywhere in their body, rather than relying solely on local surgery, local radiation, and/or chemotherapy." ~ Dr. Bruce West. ...
Organ toxicity in cancer therapy is likely caused by an underlying disposition for given pathophysiological mechanisms in the individual patient. Mechanistic data on treatment toxicity at the patient level are scarce; hence, probabilistic and translational linkages among different layers of data information, all the way from cellular targets of the therapeutic exposure to tissues and ultimately the patients organ systems, are required. Throughout all of these layers, untoward treatment effects may be viewed as perturbations that propagate within a hierarchically structured network from one functional level to the next, at each level causing disturbances that reach a critical threshold, which ultimately are manifested as clinical adverse reactions. Advances in bioinformatics permit compilation of information across the various levels of data organization, presumably enabling integrated systems biology-based prediction of treatment safety. In view of the complexity of biological responses to cancer
During high-dose chemotherapy, the patient receives high doses of chemotherapy, and possibly radiation therapy, in order to kill the cancer cells. Whi
Surgery and radiation are often used together in more advanced lesions. As combined treatment has evolved, surgery with postoperative radiation therapy is most often employed. Recent advances in reconstructive surgery have further improved functional and cosmetic outcomes.. In select instances, promising results are being obtained with combined chemotherapy and radiation therapy in an effort to avoid surgical resection.. ...
This unit (1) provides background into understanding how agents that target specific molecules or receptors (molecular‐targeted agents), in particular, agents affecting the tumor vasculature (perivasculature network in tumors), interact with and modify radiation therapy; (2) details factors affecting interpretation of results in murine tumor model experiments utilizing radiation therapy and drug combinations; and (3) provides specific protocols for the application of radiation therapy, both alone and in combination with chemotherapy and/or molecular‐targeted agents
The use of ADT for two months before and two months during RT for early PCa is associated with significantly increased overall survival.
We are thrilled to offer a wide range of the most advanced modalities that speed the healing process in conjunction with appropriate manual treatments
TY - JOUR. T1 - Intraoperative radiation therapy for breast cancer patients. T2 - Current perspectives. AU - Dutta, Sunil W.. AU - Showalter, Shayna L.. AU - Showalter, Timothy N.. AU - Libby, Bruce. AU - Trifiletti, Daniel M.. PY - 2017/4/18. Y1 - 2017/4/18. N2 - Accelerated partial breast irradiation (APBI) provides an attractive alternative to whole breast irradiation (WBI) through normal tissue radiation exposure and reduced treatment duration. Intraoperative radiation therapy (IORT) is a form of APBI with the shortest time interval, as it delivers the entirety of a planned radiation course at the time of breast surgery. However, faster is not always better, and IORT has been met with healthy skepticism. Patients treated with IORT have an increased compliance and overall satisfaction when compared to patients treated with WBI. However, early randomized trial results demonstrated an increased rate of recurrence after IORT, slowing its widespread adoption. Despite these controversies, IORT ...
Preoperative radiation therapy has shown to be of benefit for the prevention of local recurrence rates in rectal cancer patients (11, 12). Long-course preoperative chemoradiotherapy is of benefit in stage T3/T4 rectal cancer patients, and long-course preoperative chemoradiation is the standard of care in the United States (27). However, considering the extensive morbidity of preoperative radiation therapy (13-15), it is of great importance to identify patients with a low risk of local recurrence in which radiation therapy is redundant. With this intention, the current study was done in patients with stage III rectal cancer, as these patients are at the highest risk for local recurrence (12). Our results show that biochemical detection of caspase-3 levels can be used as a marker to identify patients with a very high probability for local cure with surgery alone.. To select patients who can be refrained from preoperative radiation therapy, a marker should provide accurate prediction of clinical ...
When you donate blood or platelets at the Kraft Family Blood Donor Center at Dana-Farber Cancer Institute and Brigham and Women's Hospital, or give blood on board the Dana-Farber Cancer Institute/Brigham and Women's Hospital Blood Mobile, you are making a life-saving difference for patients in need - right here in our community.
The skin rash by EGFRI is thought to be the direct consequence of the EGFR blockade in basal epidermal keratinocytes as well as the outer root sheath of hair follicles, leading to a local growth arrest and consecutive inflammation. Its occurrence may be a pharmacodynamic marker of the drug action and has been proposed as surrogate parameter of tumour response [9, 10].. EGFRI are increasingly used in parallel to, or, at least, in short sequence to radiotherapy. For example, combined treatment with cetuximab and radiotherapy has been shown to improve locoregional control in patients with squamous cell carcinoma of the head and neck in a phase 3 trial [1]. Whereas the administration of cetuximab led to a significant amount of EGFRI-induced skin rashes in the combined treatment group (8.2% vs. 0.5%, p , 0.001), no statistically significant exacerbation of radiation dermatitis was reported (23 vs. 18% grade 3-5 reactions, p = 0.27).. In recent times, however, accumulating case reports reveal grade ...
BOSTONThe Dana-Farber Cancer Institute and the National Foundation for...With eight other NFCR research centers at universities and research ho...How the Center Works...Traditionally monoclonal antibodies have been derived from mouse mode...,Dana-Farber,launches,NFCR,Center,for,Therapeutic,Antibody,Research,and,Engineering,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
A major objective of the second Intergroup Rhabdomyosarcoma Study (IRS-II) (1978 to 1984) was to preserve the bladder without compromising the survival of children with localized genitourinary sarcomas arising in or near the bladder. After incisional biopsy, 109 patients with localized, gross residual sarcoma of the prostate (43 patients), bladder (43 patients), vagina (20 patients), or cervix/uterine corpus (3 patients) were treated with vincristine, dactinomycin, and cyclophosphamide (VAC). After two to four drug courses, radiation therapy and/or surgery were used to treat patients with residual or recurrent tumor. The 3-year survival rate of patients treated on this primary chemotherapy regimen (70%) was similar to that of the primary surgery regimens of IRS-I (78%; P = 0.46), but the 3-year disease-free survival rate was significantly inferior (52% versus 70%; P = 0.02). Since the IRS-II encouraged bladder preservation at the onset of therapy, the percentage of patients with bladder and ...
Physicians, researchers, and scientists at Dana-Farber Cancer Institute and Brigham and Womens Hospital have launched one of the nations most comprehensive personalized cancer medicine initiatives.
Background: Radiotherapy (RT) is used for to treat unresectable locally advanced non-small cell lung cancer (NSCLC). For better disease control, RT has recently been combined with chemotherapy (CTx) in a variety of ways. This study examined the most effective combination methods of CTX and RT against NSCLC.. Material and Methods: Human lung cancer cell line (NCI-H520) and various chemotherapeutic agents (paclitaxel, docetaxel, gemcitabine, and cisplatin) were used in this study. The radiation doses used were 0, 2, 4 and 8 Gy. After processing of various combinations according to the radiation dose and concentrations of chemotherapeutic agents, the level of cell survival was quantified by a MTT assay. The combination index was calculated using the Chou and Talalay method on Calcusyn software and used to examine the synergism between CTx and RT.. Results: Among the various combinations of chemotherapeutic agents and radiation doses, concurrent chemoradiation therapy (CCRT) led to the highest rate ...
The ASCO Endorsement Panel emphasized the potential benefits of chemotherapy for women with high-risk early-stage or advanced disease. The GOG-122 trial compared whole-abdominal radiation therapy with doxorubicin and cisplatin chemotherapy in women with stage III or IV endometrial cancer and ≤ 2 cm of postoperative residual disease. Stage-adjusted results suggested that chemotherapy was associated with higher progression-free and overall survival, but also higher rates of acute toxicity.12 In the JGOG 2033 (Japanese Gynecologic Oncology Group) trial, women with stage IC to IIIC endometrial cancer were randomly assigned to pelvic radiotherapy or cyclophosphamide, doxorubicin, and cisplatin chemotherapy. The overall results demonstrated no statistically significant difference between study arms in progression-free or overall survival, suggesting that either treatment approach is reasonable.13 However, in a higher-risk subgroup, defined as either patients age , 70 years with stage IC or grade 3 ...
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration AbbVie and Harpoon Therapeutics announced that they have entered an immuno-oncology research collaboration. [AbbVie, Inc.] Press Release Dana-Farber Cancer Institute Joins the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy announced that researchers at Dana-Farber Cancer Institute have joined its network. Dana-Farber is a leader in cancer research and brings a team of experts who will collaborate with Parker Institute investigators to enhance and expand research projects and clinical trials. [Dana-Farber Cancer Institute] Press Release Kites Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy Kite announced that the FDA has granted regular approval to Yescarta™, the first CAR T therapy for the treatment of adult ...
Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: a pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven
Find about Multidisciplinary Treatments and other important information you need to know about St. Joseph Hospitals Liver Tumor Program in Orange County.
Preliminary results of a Radiation Therapy Oncology Group trial (RTOG) 9705, a phase II study of postoperative adjuvant therapy in patients with completely reseted stage II and stage IIIA non-small cell lung cancer ...
Clinical trial for Malignant neoplasm of brain , An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo for Newly Diagnosed Patients With Glioblastoma (GBM a Malignant Brain Cancer)
Clinical trial for Malignant neoplasm of brain , An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo for Newly Diagnosed Patients With Glioblastoma (GBM a Malignant Brain Cancer)
To determine the long-term outcome of a consistent treatment approach with electron beam postmastectomy radiation therapy (PMRT) in breast cancer patients with , or =10 positive nodes treated with combined-modality therapy.TSixty-three breast cancer patients with , or =10 positive lymph nodes were treated with combined-modality therapy using an electron beam en face technique for PMRT at the University of Florida. Patterns of recurrence were studied for correlation with radiation fields. Potential clinical and treatment variables were tested for possible association with local-regional control (LRC), disease-free survival (DFS), and overall survival (OS).TAt 5, 10, and 15 years, OS rates were 57%, 36%, and 27%, respectively; DFS rates were 46%, 37%, and 34%; and LRC rates were 87%, 87%, and 87%. No clinical or treatment variables were associated with OS or DFS. The use of supplemental axillary radiation (SART) (p = 0.012) and pathologic N stage (p = 0.053) were associated with improved LRC. ...
Randomized. 524 patients with NSCLC Stage IIIA (33%) or resectable IIIB (67%). Arm 1) Induction cisplatin 55 mg/m2 + etoposide 100 mg/m2 x3 cycles, then concurrent RT 45/30 in 1.5 Gy BID with carboplatin 100 mg/m2 + vindesine 3mg, followed by surgery vs. Arm 2) Same induction, followed by surgery, followed by RT (54/30 if R0, 68.4/38. Surgery after 4-6 weeks. Primary endpoint PFS ...
(A) Overall survival, disease-free survival, and loco-regional control rates after definitive radiotherapy for vaginal cancer. (B, C) Overall survival and disea
PRIMARY OBJECTIVES:I. To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than
Called "beige fat," the cells are found in scattered pea-sized deposits beneath the skin near the collarbone and along the spine in adult humans. Because this type of fat can burn off calories - rather than store them, as "white fat" cells do - beige fat cells might spawn new therapies for obesity and diabetes, according to researchers led by Bruce Spiegelman, PhD, of Dana-Farber.. Spiegelman is the senior author of a report scheduled for advance online publication on July 12 by the journal Cell. The print issue of Cell will publish on July 20.. The study found that beige fat is genetically distinct from "brown fat," which also burns calories to generate heat. Brown fat is found in small mammals and human infants, where it protects against harm from cold. White fat, on the other hand, stores calories, and excess white fat contributes to obesity.. Existence of this third type of fat (in addition to white and brown) had been proposed in a paper by Spiegelmans lab in 2008, but the Dana-Farber team ...
Christine Jaworek-Lopes was moved when she believed her 9-year-old son, Zachary, was writing a school paper about her experiences as a stage IV colon cancer patient at Dana-Farber/Brigham and Womens Cancer Center (DF/BWCC). Upon learning what he was really up to, she was stunned. Unbeknownst to his parents, the third-grader […] ...
Health,Scientists at the Dana-Farber Cancer Institute have identified a prote... Identification of this HIV-blocking factor opens many new avenues...,HIV,blocking,protein,in,Monkey,,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
In this manuscript, we show that treatment with low doses of fractionated radiotherapy leads to upregulation of PD-L1 expression on tumor cells secondary to CD8+ T-cell production of IFNγ. In models of melanoma, colorectal, and breast cancer, we demonstrate that the efficacy of radiotherapy can be enhanced through combination with αPD-L1 mAb, leading to the generation of memory immunity in LTS mice capable of protecting against tumor recurrence. Furthermore, our data reveal that dose scheduling may be critical for outcome with concurrent but not sequential therapy effective at improving local tumor control and survival.. Recent clinical trials have begun to evaluate blockade of the PD-1/PD-L1 axis with encouraging responses observed in multiple disease settings with mAb targeted against both PD-1 and PD-L1 (18-20, 24, 25). Despite this, combination approaches may be required to improve response rates and to generate durable antitumor immunity. We and others have demonstrated the potential to ...
Cancer survivors of all ages sometimes face psychological, social, or physical side effects that are long-lasting or develop later in life. With the number of survivors reaching 12 million in the U.S. today, the need for survivorship care and education is growing. "Survivorship care is not a one-size-fits-all approach. Just […] ...
After matching at a 1:2 ratio, 150 patients were treated with CCRT and 75 with CCRT plus C were selected. The 3-year PFS rates (83.7% vs 72.0%, P = 0.036) and 3-year LRFS rates (98.6% vs 90.2%, P = 0.034) were higher for patients in the CCRT plus C arm than with CCRT alone. Furthermore, a marginal trend of increasing risk of 3-year DMFS rates (83.9% vs 78.4%, P = 0.301) and 3-year OS rates (91.2% vs 85.8%, P = 0.123) was found. The results indicated that CCRT plus C treatment was a significant and independent protective predictor for 3-year PFS (P = 0.015) and LRFS rates(P = 0.047). When focusing on stage T4 and/or N3 in the subgroup, the CCRT plus C arm achieved significantly prolonged 3-year PFS (79.9% vs 62.6%, P = 0.022) and a marginally increased OS (88.0% vs 77.9%, P = 0.086) compared with that of CCRT alone. Additionally, the 3-year LRFS (97.0% vs 90.9%, P = 0.246) and DMFS (79.9% vs 67.8%, P = 0.161) were enhanced in patients with CCRT plus C compared to CCRT alone. When concentrating on ...
Find local Radiation Oncologists practicing in Elk City, OK. Read ratings and reviews to help find the best Radiation Oncologist in your area.
Chemotherapy is a systemic method of cancer treatment, in contrast with local therapies such as surgery and radiation therapy. The drugs used in chemotherapy are able to reach most parts of the body. Therefore, chemotherapy is likely to be recommended for cancer that has already spread to other areas of the body, for tumors that occur at more than one site, or for tumors that cannot be removed surgically. It is also used when a patient has recurrent disease after initial treatment with surgery or radiation therapy.. Chemotherapy is less mutilating than surgery and helps conserve organ or limb function since anti-cancer drugs are used to act on cancer cells without direct removal of a body part.. For some cancers, chemotherapy alone can destroy all the cancer cells and cure the cancer (primary treatment). As an adjuvant treatment, chemotherapy is given prior to, or after other methods, to increase the effectiveness of cancer treatment. Most often, adjuvant chemotherapy is given after other ...
The Ogino MPE Lab and the Program in MPE Molecular Pathological Epidemiology host the International Molecular Pathological Epidemiology (MPE) Meeting Series. ...
Find 5 local Radiation Oncologists practicing in Ypsilanti, MI. Read ratings and reviews to help find the best doctor in your area.
Find 5 local Radiation Oncologists practicing in Stockton, CA. Read ratings and reviews to help find the best doctor in your area.
A number of factors may be behind underutilization of trimodality treatment in such patients, she said in an interview, emphasizing the need for criteria and the importance of developing biomarkers for IBC to help oncologists better recognize and differentiate such cancer patients at the earliest possibility.. "We need to identify these patients, especially women with aggressive IBC, and ensure they are receiving all of the treatment options available. We know that trimodality treatment is best for optimizing survival, yet many women are not being given that opportunity-for whatever reasons. Having biomarkers for IBC and implementing criteria would surely help, but right now we have neither.". The study included only women who had access to medical care who were clinically well enough to undergo aggressive treatment; excluded were those with advanced disease; those who had disease progression while on chemotherapy, rendering them nonsurgical candidates; and those in such a medically frail ...
Steven A. Rosenberg, MD In the past two decades significant progress has quality of life. The use of local radiation therapy has occurred, in the management of patients with mus- had a profound impact on the ability to achieve local loskeletal cancers, that has improved both the survival control.
Radiotherapy has been considered a local modality and outcomes have emphasized local and regional control of tumors. Recent data suggests that radiotherapy may activate the immune system and the combination of radiation therapy and immune therapies may have the potential to improve both local and distant control of tumor deposits. Below we review principals underlying the concepts of combining both modalities.
Interfacing Commitment. GE is obligated to provide Interfacing information and data (such as protocol information) necessary to ensure an open Interface between GEs existing and future devices and third parties devices in certain product combinations, and new Interfacing information relating to any Interface modification or upgrade of GEs devices.. Interfacing Commitment Overview ...
The role of radiotherapy (RT) as an adjuvant to surgical options in the treatment of locally advanced rectal cancer has been established as it reduces local recurrence when combined with surgical resection and enhances survival when used in multidisciplinary treatment. However, many issues need to be addressed; some of these can render RT unnecessary, whereas others can reveal a new role of RT in rectal cancer. This review will discuss not only the basic role of RT but also the associated but controversial issues in detail in an attempt to find answers and determine future directions for the next decade ...
Slagel, D E.; Feola, J; Houchens, D P.; and Ovejera, A A., "Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft mode." (1982). Subject Strain Bibliography 1982. 3010 ...
This randomized phase II trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy
Conclusions: The intensified treatment paradigm of XELOX concurrent chemoradiation followed by one cycle of consolidation chemotherapy was well tolerated in our cohort and provided a promising long-term oncologic outcome, which warranted further investigation in a randomize trails....
Evidence-based Series 7-3 Version [TO BE UPDATED] A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Management of Unresected Stage Ill Non-Small Cell Lung
The size, stage, rate of growth, and other characteristics of the tumor determine the kinds of treatment. Treatment may include surgery, drugs (hormonal therapy and chemotherapy), radiation and/or immunotherapy. Surgical removal of the tumor provides the single largest benefit, with surgery alone being capable of producing a cure in many cases. To somewhat increase the likelihood of long-term disease-free survival, several chemotherapy regimens are commonly given in addition to surgery. Most forms of chemotherapy kill cells that are dividing rapidly anywhere in the body, and as a result cause temporary hair loss and digestive disturbances. Radiation is indicated especially after breast conserving surgery and substantially improves local relapse rates and in many circumstances also overall survival. Some breast cancers are sensitive to hormones such as estrogen and/or progesterone, which makes it possible to treat them by blocking the effects of these hormones ...
Phase III Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer
When physician-scientist Jay Bradner left the Dana-Farber Cancer Institute last year, he left behind some key scientific work that had already intrigued a
High-dose chemotherapy can cause damage directly to the cells of the lungs. This may be more frequent in patients treated with certain types of chemotherapy and/or radiation therapy. This complication may occur anytime from a few days after high-dose chemotherapy to several months after treatment. Patients typically experience a dry, non-productive cough or shortness of breath. Sometimes, patients and their doctors often misinterpret these early symptoms. Patients experiencing shortness of breath or a new cough after allogeneic transplant should bring this to the immediate attention of their doctors since this can be a serious and even fatal complication ...
One hundred and seventy two patients with T2-3N + /-M0 distal rectal cancer had been enrolled. In Group 1 the number of patients was 127, in Group 2 - 45 patients. SSO in Group 1 comprised 43.3% in Group 2 - 91.1% (p> 0.05). A significant increase of SSO rates in women (64.5%) than men (48.9%) was observed (p = 0.04). Age, stage, tumor differentiation, the type of spread didnt affect the SSO rate. ...
Harvard researchers at Dana-Farber Cancer Institute (DFCI) have identified a number of cancer genes that endow melanoma tumors with the ability to metastasize, making it possible to predict whether the tumors are likely to spread.
Scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers, a sign that it might contribute to the disease and potentially be a key to diagnosing, preventing, and treating it ...
Highland Pharms Therapy Plus large size (4oz), an Ultra-Rich CBD Cream infused with Essential Oils for added benefit. FREE SHIPPING!
Regression of a disseminated tumour following inter-current infection and prolonged high fever was first reported by BUSCH over 100 years ago. In 1893 COLEY confirmed this observation and in a series...
New Treatment Modalities and Centers. A Brand new GammaKnife treatment center has been completed and is now available for clinical treatments. The GammaKnife Center is located on the main campus and more information can be found here. The facility construction of an innovative Proton Beam Treatment center is expected to completed by 2013. We are very excited that we will be able to provide the state of the art radiotherapy modality to the cancer patients in New Jersey and surrounding areas.. ...
Rockville, MD (PRWEB) October 19, 2010 -- CME Outfitters, LLC, (CMEO) an award-winning accredited provider of multidisciplinary continuing education (CE), is
Hi, Help! I have completed all of my care plan but cant find the multidisciplinary treatment plan for G.I. Bleeding. Upper. That was the primary diagnosis and the secondary was pancreatitis
It is well-established that nasopharyngeal carcinoma (NPC) is a chemo-responsive disease. Despite improved outcome with chemo-radiation (platimum-based chemotherapy with radiation), treatment failure continue to be a problem in patients with locally advanced Stage III/IV disease. Now, a new study published … Continue reading →. ...
In this paper we propose a multimodal approach to distinguish between movements displaying three different expressive qualities: fluid, fragmented, and impulsive movements. Our approach is based on th
Surgery for nasopharyngeal cancer is not common because the area is difficult to get to and it is close to important nerves and blood vessels. Surgery may be needed, if the cancer returns after previous treatment with radiation therapy ...
A method for co-registering multimodality imaging planes using fiducial markers is provided. A lateral transfer board which is used to move a patient f...